Tempus AI has agreed to acquire Personalis, a maker of cancer tests, in a deal valued at $1.5 billion, according to BioPharma Dive.
The two companies both work in cancer diagnostics — the field of tests that help detect disease, guide treatment decisions, and track how a patient is responding to therapy. By folding Personalis into its business, Tempus AI adds another cancer-testing capability to its portfolio.
BioPharma Dive reports that the planned acquisition follows recent interest in blood-based cancer tests across the medtech industry. These tests, sometimes described broadly as ways to look for signs of cancer in a blood sample rather than through more invasive procedures, have drawn growing attention from companies competing in the diagnostics space. Tempus AI's move to buy Personalis fits into that broader wave of industry activity.
The reported deal value — $1.5 billion — signals how much Tempus AI is willing to pay to expand in this area, though the transaction is described as planned, meaning it still has to be completed.
Why it matters: consolidation among cancer-test makers like this one could shape which diagnostic tools reach patients and doctors, as major players race to build out blood-based testing that promises earlier, less invasive ways to detect and monitor cancer.